Comparative effectiveness of bevacizumab plus cisplatin-based chemotherapy versus pemetrexed plus cisplatin treatment in East Asian non-squamous non-small cell lung cancer patients applying real-life outcomes

Asia-Pacific Journal of Clinical Oncology

Volumn 7, Issue SUPPL.2, 2011, Pages 34-40

  Chang, Gee Chen ^a,b   Ahn, Myung Ju ^c   Wright, Elaine ⁱ   Kim, Heung Tae ^g   Kim, Joo Hang ^d   Kang, Jin Hyoung ^e   Kim, Sang We ^f   Sherman, Steven ^h   Walzer, Stefan ⁱ  

^a TAICHUNG VETERANS GENERAL HOSPITAL   (Taiwan)

^b NATIONAL YANG MING UNIVERSITY   (Taiwan)

^c Samsung Medical Center   (South Korea)

^d Yonsei University College of Medicine   (South Korea)

^e The Catholic University of Korea   (South Korea)

^f University of Ulsan College of Medicine   (South Korea)

^g National Cancer Center   (South Korea)

^h Analytica International Inc   (United States)

ⁱ F HOFFMANN LA ROCHE LTD   (Switzerland)

Author keywords

Antineoplastic combined chemotherapy protocol; Asia; Bevacizumab; Comparative study; Non small cell lung carcinoma

Indexed keywords

BEVACIZUMAB; CISPLATIN; PEMETREXED;

ADULT; ARTICLE; ASIAN; CANCER CHEMOTHERAPY; CANCER PATIENT; CANCER SURVIVAL; COMPARATIVE STUDY; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; HUMAN; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; METASTASIS; MIXED CELL CULTURE; PHASE 4 CLINICAL TRIAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RECURRENT CANCER; TREATMENT OUTCOME;

ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, NON-SMALL-CELL LUNG; CISPLATIN; DISEASE-FREE SURVIVAL; FAR EAST; FEMALE; GLUTAMATES; GUANINE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; SURVIVAL ANALYSIS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 79956091519     PISSN: 17437555     EISSN: 17437563     Source Type: Journal    
DOI: 10.1111/j.1743-7563.2011.01400.x     Document Type: Article

References (21)

1. Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM. GLOBOCAN 2008, Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 10. International Agency for Research on Cancer, Lyons, France 2008 [cited 14 April 2011]. Available from: .
2. SEER Cancer. Statistics review 1957-2007. National Cancer Institute 2011. [Cited 14 April 2011 Available from: .
3. Hirsch FR, Spreafico A, Novello S, Wood MD, Simms L, Papotti M. The prognostic and predictive role of histology in advanced non-small cell lung cancer: a literature review. J Thorac Oncol 2008; 3: 1468-81.
4. Crino L, Dansin E, Garrido P etal. Safety and efficacy of first-line bevacizumab-based therapy in advanced non-squamous non-small-cell lung cancer (SAiL, MO19390): a phase 4 study. Lancet Oncol 2010; 11: 733-40.
5. Nishio M, Horai T, Kunitoh H etal. Randomized, open-label, multicenter phase II study of bevacizumab in combination with carboplatin and paclitaxel in chemotherapy-naive Japanese patients with advanced or recurrent nonsquamous non-small cell lung cancer (NSCLC): JO19907. J Clin Oncol 2009; 27: abstr 8036.
6. Reck M, von Pawel J, Zatloukal P etal. Phase III trial of cisplatin plus gemcitabine with either placebo or bevacizumab as first-line therapy for nonsquamous non-small-cell lung cancer: AVAil. J Clin Oncol 2009; 27: 1227-34.
7. Reck M, von Pawel J, Zatloukal P etal. Overall survival with cisplatin-gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL). Ann Oncol 2010; 21: 1804-9.
8. Sandler A, Gray R, Perry MC etal. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med 2006; 355: 2542-50.
9. Walzer S, Vergnenègre A, Chouaid C etal. An indirect comparison of the efficacy of bevacizumab plus cisplatin and gemcitabine (BCG) or bevacizumab plus carboplatin and paclitaxel (BCP) versus pemetrexed plus cisplatin (PC) and cetuximab plus vinorelbine and cisplatin (CVC) in patients (pts) with advanced or recurrent non-small cell cancer (NSCLC). 2009. European Society for Medical Oncology (ESMO) 20-24 September 2009 Berlin.
10. Mok TS, Wu YL, Thongprasert S etal. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med 2009; 361: 947-57.
11. Wu Y-LACC, Au JS-K, Zhu Y, Tsai C-M. Final safety data for Chinese patients (pts) with non-squamous non-small cell lung cancer (NSCLC) who received first-line bevacizumab (Bv) plus chemotherapy in SAiL (MO10390). 2010. European Lung Cancer Conference 2010.
12. Scagliotti GV, Parikh P, von PJ etal. Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer. J Clin Oncol 2008; 26: 3543-51.
13. Yang CH, Simms L, Park K, Lee JS, Scagliotti G, Orlando M. Efficacy and safety of cisplatin/pemetrexed versus cisplatin/gemcitabine as first-line treatment in East Asian patients with advanced non-small cell lung cancer: results of an exploratory subgroup analysis of a phase III trial. J Thorac Oncol 2010; 5: 688-95.
14. Berenson K, Vergnenègre A, Sherman S, Walzer S. First-line bevacizumab-based therapy versus pemetrexed + cisplatin for the treatment of advanced adenocarcinoma non-squamous non-small cell lung cancer: indirect comparison applying real-life outcomes. 2010. ISPOR 13th European Congress 6-7 November 2010.
15. Signorovitch J. Robust comparative effectiveness without head-to-head trials: leveraging. Primary clinical trial data for indirect comparisons. 2011. iHEA 7th World Congress on Health Economics, 12-15 July Beijing.
16. SAS (computer program). Version 9.2 SAS Institute Inc, Cary, NC, USA 2008.
17. Department of Health and Ageing. Guidelines for preparing submissions to the Pharmaceutical Benefits Advisory Committee (version 4.3) 2008. Therapeutic Goods Administration, Australian Government, Canberra 2008.
18. Glenny AM, Altman DG, Song F etal. Indirect comparisons of competing interventions. Health Technol Assess 2005; 9: i-iv.
19. Wells GA, Sultan SA, Chen L, Khan M, Coyle D. Indirect Evidence: Indirect Treatment Comparisons in Meta-Analysis. Canadian Agency for Drugs and Technologies in Health (CADTH), Ottawa 2009.
20. Chang JW-C, Thongprasert S, Wright E etal. An indirect comparison of bevacizumab plus cisplatin-gemcitabine and cisplatin plus pemetrexed treatment for patients with advanced first-line non-squamous non-small cell lung cancer in East Asia. Asia-Pac J Clin Oncol 2011; 7(Suppl. 2): 13-21.
21. Scagliotti G, Hanna N, Fossella F etal. The differential efficacy of pemetrexed according to NSCLC histology: a review of two phase III studies. Oncologist 2009; 14: 253-63.